103 related articles for article (PubMed ID: 10832440)
1. [Histoculture drug response assay on non-small cell lung cancer].
Yoshimasu T; Oura S; Maebeya S; Tanino H; Bessho T; Arimoto J; Sakurai T; Matsuyama K; Naito Y; Furukawa T; Yano T; Suzuma T; Hirai I
Gan To Kagaku Ryoho; 2000 May; 27(5):717-22. PubMed ID: 10832440
[TBL] [Abstract][Full Text] [Related]
2. [High clinical predictability of histoculture drug response assay (HDRA) for drug-sensitivity of cancer of the digestive organs].
Kubota T; Furukawa T; Kitajima M
Gan To Kagaku Ryoho; 1993 Mar; 20(4):461-6. PubMed ID: 8452384
[TBL] [Abstract][Full Text] [Related]
3. [In vitro drug sensitivity testing and chemotherapy of lung cancer].
Liao ML
Zhonghua Jie He He Hu Xi Za Zhi; 1993 Dec; 16(6):345-6, 374. PubMed ID: 8033231
[TBL] [Abstract][Full Text] [Related]
4. [Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer--a case report].
Tanino H; Miyoshi S; Furukawa T; Bessho T; Maebeya S; Suzuma T; Hirai I; Arimoto J; Harada N; Hoso T; Naito Y
Gan To Kagaku Ryoho; 1997 May; 24(7):861-4. PubMed ID: 9170526
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
8. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].
Zhang J; Ji J; Ji YB; Yuan F; Liu BY; Zhu ZG; Lin YZ
Ai Zheng; 2005 Apr; 24(4):432-7. PubMed ID: 15820065
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.
Higashiyama M; Kodama K; Yokouchi H; Takami K; Doi O; Kobayashi H; Tanisaka K; Minamigawa K
J Surg Oncol; 1998 May; 68(1):19-24. PubMed ID: 9610658
[TBL] [Abstract][Full Text] [Related]
11. Clinical Usefulness of the Histoculture Drug Response Assay for Breast Cancer.
Hoffman RM; Tanino H
Methods Mol Biol; 2018; 1760():93-100. PubMed ID: 29572797
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
13. [Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Miyagi M; Soda T; Nakashima T
Nihon Jibiinkoka Gakkai Kaiho; 1994 Dec; 97(12):2247-58. PubMed ID: 7861297
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
15. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
16. [The effect of the histoculture drug response assay (HDRA) based perioperative chemotherapy for non-small cell lung cancer].
Tanahashi M; Yamada T; Moriyama S; Suzuki E; Niwa H
Kyobu Geka; 2008 Jan; 61(1):26-30. PubMed ID: 18186269
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors.
Itaya M; Yoshimoto J; Kojima K; Futagawa S
Oncol Rep; 1999; 6(3):675-82. PubMed ID: 10203614
[TBL] [Abstract][Full Text] [Related]
18. Data acquisition for the histoculture drug response assay in lung cancer.
Yoshimasu T; Oura S; Hirai I; Tamaki T; Kokawa Y; Hata K; Ohta F; Nakamura R; Kawago M; Tanino H; Okamura Y; Furukawa T
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):303-8. PubMed ID: 17258552
[TBL] [Abstract][Full Text] [Related]
19. [Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
Chen W; Zhou X; Xu Q; Guo W; Lin L
Zhonghua Kou Qiang Yi Xue Za Zhi; 2002 Nov; 37(6):404-7. PubMed ID: 12641948
[TBL] [Abstract][Full Text] [Related]
20. Clinical Correlation of the Histoculture Drug Response Assay for Head and Neck Cancer.
Hoffman RM
Methods Mol Biol; 2018; 1760():83-92. PubMed ID: 29572796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
